回复 David_2009 的帖子
A comment by our MEdHelp friend, studyforhope, on the efficacy of REP9AC:
The artificial temporary blocking of surface antigen release unleashes a powerful immune response against previously unattacked HbSAg epitopes ( by Tcell exhaustion (class I and II!) by antigen overexposure and other blocking effects) and other portions of the surface antigen.
When this effect is insufficient to reduce the VL to UND - as was the case in 4 out of the seven - we must assume an adaptive response in the viral genome of the critical response elements in the surface antigen protein so as to evade some of the immunological mechanisms now present
or
an inherent incapacity of a particular patient to mount a suffcient strength response regardless of resistance adaptations in the surface antigen response elements.
the first problem could be overcome by antiviral cotreatment to reduce the adaptive/mutational power. Then the HBV system will respond to the desired end -UND and SVR.
The second situation is hopefully rare. Since a substantial reduction in cccDNA during replicor therapy is nevertheless expected to happen in most of such patients, the maintenance of that blissful state will have to come by external help, that is by continuing antivirals or hopefully with a permanent reinfection blocker -likely Myrcludex- that has -again hopefully- less side effects than lifelong antivirals.
Overall the surface antigen blockage should become a powerful new tool , used wisely in optimized combinations to achieve a state of permanently improved health for chronic HBV patients. 我们MEdHelp朋友，studyforhope，一个REP9AC疗效评价：
表面抗原释放的人工暂堵释放出一个强大的免疫反应，对以前unattacked的乙肝表面抗原表位（Tcell用尽抗原曝光过度和其他阻断作用（I类和II））和其他部分的表面抗原。
当这种影响是不够的，以减少对VL(viral load) to UND(undetected) - 的情况一样，在4/7个 - 我们必须假设病毒基因组中的关键反应元件的表面抗原蛋白的适应性反应，以逃避一些现在提出免疫机制
或
固有的特定病人丧失工作能力，不管阻力适应安装足够的强度响应表面抗原反应元素。
第一个问题是可以克服抗病毒药物cotreatment减少自适应/突变
功率
。 HBV的系统，然后将响应所需的结束，UND(undetected)和SVR。
第二种情况是希望罕见。由于在cccDNA的replicor治疗期间的大幅减少但预计在大多数这类病人发生，维护，幸福的状态，或希望与一个永久的再感染受体阻滞剂可能会向外部的帮助下，继续抗病毒药物来Myrcludex已再次希望小于终身抗病毒药物的副作用。
总体而言，表面抗原堵塞应成为一个强大的新工具，用于明智的优化组合，以实现永久改善慢性乙型肝炎患者的健康状态。 | 
楼主: cshbv
发表于 2011-12-18 01:55
